Vasculitis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Intervention:   Drug: [14C]CCX168 Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Condition:   Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Interventions:   Drug: CCX168;   Drug: Midazolam;   Drug: Celecoxib;   Drug: Itraconazole;   Drug: Rifampicin Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials